Inhibrx (INBX)

• Market cap: $1.17B
• 1 day: -0.19%
• 5 days: -6.35%
• 1 month: -4.12%
• 3 months: 145.44%
• 6 months: 442.33%
• Year to date: 425.97%
• 1 year: 436.88%
• 5 years: 541.17%
• 10 years: 541.17%
• Sector: Healthcare
• Industry: Biotechnology

About: Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Employees: 161